抗乙肝病毒对肝癌TACE术后复发转移的治疗效果与免疫功能影响的研究

发布时间：2018-03-07 08:00

本文选题：HBV相关性肝癌　切入点：抗病毒治疗　出处：《中华医院感染学杂志》2017年14期 　论文类型：期刊论文

【摘要】：目的观察并分析抗乙肝病毒治疗对乙肝病毒(HBV)相关性肝癌肝动脉化疗栓塞术(TACE)后肿瘤复发转移和免疫功能的影响,为临床治疗提供参考依据。方法选取医院2014年3月-2015年6月应用TACE术后接受抗病毒治疗的70例患者为抗病毒组,将TACE术后未接受抗病毒治疗的76例患者为对照组,比较两组患者临床指标,同时随访12个月以上,比较两组患者近期疗效和肿瘤复发转移情况。结果与治疗前比较,治疗后抗病毒组CD_3~+、CD_4~+/CD_8~+、NK显著上升,治疗后抗病毒组CD_3~+、CD_4~+/CD_8~+、NK显著高于对照组(P0.05);抗病毒组临床治疗总有效率为68.57%显著高于对照组51.32%,复发率为48.57%显著低于对照组67.11%(P0.05)。结论抗乙肝病毒治疗能够有效防止乙肝病毒被激活,对于改善HBV相关性肝癌预后具有促进效果。
[Abstract]:Objective to observe and analyze the effect of anti-HBV therapy on tumor recurrence, metastasis and immune function after TACE-associated hepatic artery chemoembolization (TACEE) for hepatocellular carcinoma associated with hepatitis B virus (HBV). Methods from March 2014 to June 2015, 70 patients who received antiviral therapy after TACE were selected as antiviral group and 76 patients who were not treated with antiviral therapy after TACE as control group. The clinical indexes of the two groups were compared and followed up for more than 12 months. The short-term curative effect and tumor recurrence and metastasis were compared between the two groups. Results compared with those before treatment, CD3 ~ + CD4 ~ / CD8 ~ NK increased significantly in the antiviral group. The total effective rate of clinical treatment in the antiviral group was 68.57% significantly higher than that in the control group (51.32%), and the recurrence rate was 48.57% significantly lower than that in the control group (67.11% P 0.05). Conclusion Anti-hepatitis B virus therapy can effectively prevent the activation of hepatitis B virus, and the total effective rate of clinical treatment in the antiviral group is significantly higher than that in the control group, and the recurrence rate is significantly lower than that in the control group. It can improve the prognosis of HBV associated liver cancer.
【作者单位】：海南省人民医院放射介入科;
【基金】：海南省社会发展科技专项基金资助项目(2015SF02)
【分类号】：R512.62;R735.7

【参考文献】